RESUMEN
We report an approximated analytical solution for a single-probe four-state atomic magnetometer where no analytical solution exists. This approximated analytical solution demonstrates excellent accuracy in broad probe power and detuning ranges when compared with the numerical solution obtained using a 4th order Runge-Kutta differential equation solver on MATLAB. The theoretical framework and results also encompass widely applied single-probe three-state atomic magnetometers for which no analytical solution, even approximated, is available to date in small detuning regions.
RESUMEN
Causes and treatments for heart failure (HF) have been investigated for over a century culminating in data that have led to numerous pharmacological and surgical therapies. Unfortunately, to date, even with the most current treatments, HF remains a progressive disease with no therapies targeting the cardiomyocytes directly. Technological advances within the past two to three years have brought about new paradigms for treating many diseases that previously had been extremely difficult to resolve. One of these new paradigms has been a shift from pharmacological agents to antisense technology (e.g., microRNAs) to target the molecular underpinnings of pathological processes leading to disease onset. Although this paradigm shift may have been postulated over a decade ago, only within the past few years has it become feasible. Here, we show that miRNA106a targets genes that, when misregulated, have been shown to cause hypertrophy and eventual HF. The addition of miRNA106a suppresses misexpressed HF genes and reverses hypertrophy. Most importantly, using a cardiac targeting peptide reversibly linked to miRNA106a, we show delivery is specific to cardiomyocytes.